Giltuss TR
- Product NDC
- 58552-355
- 11-digit product format
- 585520355
- Labeler code
- 58552
- Product ID
- 58552-355_5d179277-c695-964e-e063-6294a90a7348
- Type
- HUMAN OTC DRUG
- Nonproprietary name
- Guaifenesin,Dextromethorphan HBr,Phenylephrine HCl
- Dosage form
- TABLET
- Route
- ORAL
- Labeler
- Gil Pharmaceutical Corp
- Application
- M012
- Marketing category
- OTC MONOGRAPH DRUG
- Marketing start
- 2026-10-01
- Substance
- GUAIFENESIN; DEXTROMETHORPHAN HYDROBROMIDE; PHENYLEPHRINE HYDROCHLORIDE
- Active strength
- 390; 29; 10 mg/1; mg/1; mg/1
- Pharmacologic classes
- Adrenergic alpha1-Agonists [MoA], Decreased Respiratory Secretion Viscosity [PE], Expectorant [EPC], Increased Respiratory Secretions [PE], Sigma-1 Agonist [EPC], Sigma-1 Receptor Agonists [MoA], Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC], Uncompetitive NMDA Receptor Antagonists [MoA], alpha-1 Adrenergic Agonist [EPC]
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Giltuss TR
- Listing expiration
- 2027-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| GUAIFENESIN | 390 mg/1 |
| DEXTROMETHORPHAN HYDROBROMIDE | 29 mg/1 |
| PHENYLEPHRINE HYDROCHLORIDE | 10 mg/1 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Packages#
| Package NDC | 11-digit format | Description | Units | Marketing start | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|
| 58552-355-01 | 58552035501 | 100 TABLET in 1 BOTTLE (58552-355-01) | 100 tablet | 2026-10-01 | No | No | Current |
| 58552-355-02 | 58552035502 | 2 TABLET in 1 BLISTER PACK (58552-355-02) | 2 tablet | 2026-10-01 | No | No | Current |